Reported Merck Interest in Revolution Medicines – Market Signals for 2026 Biotech M&A Deal Structures and Negotiation Strategy
Dear Clients,
Israeli healthcare and life sciences companies increasingly operate with a global footprint, with clinical development, commercialization planning, vendors, and strategic partners across the United States and Europe.
Against that backdrop, this client update flags a recent press report on potential acquisition discussions in the oncology biotech space and highlights practical deal term and process takeaways that may be relevant to Israeli companies preparing for cross border partnering, licensing, strategic investment or M&A transactions.
We hope you find this update useful and would be happy to discuss any questions or transaction readiness considerations it may raise.
Agmon With Tulchinsky
More Relevant Media
29.12.2025
EU Commission’s Medical Devices Regulation Simplification Proposal and EUDAMED Mandatory Modules Timeline
Client updates
21.07.2025
Amendment to the Medical Information Portability Law, 5784-2024 – Client Update – July 2025
Client updates
09.01.2025
FDA Guidance – Clinical Trial Diversity Action Plans – Client Update – January 2025
Client updates
15.10.2024
EU AI Act and its Impact on Israeli Companies in the Pharma and Medical Device Sector
Publications